Iron overload in myelodysplastic syndromes

References

• Heaney M L, Golde D W. Myelodysplasia. N Engl J Med 1999; 340: 1649–1660
   PubMed Web of Science ®Google Scholar
• Steensma D P, Bennett J M. The myelodysplastic syndromes: diagnosis and treatment. Mayo Clin Proc 2006; 81: 104–130
   PubMed Web of Science ®Google Scholar
• Sperr W R, Wimazal F, Kundi M, Fonatsch C, Thalhammer-Scherrer R, Schernthaner G H, et al. Survival analysis and AML development in patients with de novo myelodysplastic syndromes: comparison of six different prognostic scoring systems. Ann Hematol 2001; 80: 272–277
   PubMed Web of Science ®Google Scholar
• Kerkhofs H, Hermans J, Haak H L, Leeksma C H. Utility of the FAB classification for myelodysplastic syndromes: investigation of prognostic factors in 237 cases. Br J Haematol 1987; 65: 73–81
   PubMed Web of Science ®Google Scholar
• Nosslinger T, Reisner R, Koller E, Gruner H, Tuchler H, Nowotny H, et al. Myelodysplastic syndromes, from French – American – British to World Health Organization: comparison of classifications on 431 unselected patients from a single institution. Blood 2001; 98: 2935–2941
   PubMed Web of Science ®Google Scholar
• Greenberg P, Cox C, LeBeau M M, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079–2088
   PubMed Web of Science ®Google Scholar
• Harris N L, Jaffe E S, Diebold J, Flandrin G, Muller-Hermelink H K, Vardiman J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17: 3835–3849
   PubMed Web of Science ®Google Scholar
• List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006; 355: 1456–1465
   PubMed Web of Science ®Google Scholar
• Malcovati L, Porta M G, Pascutto C, Invernizzi R, Boni M, Travaglino E, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005; 23: 7594–7603
   PubMed Web of Science ®Google Scholar
• Park C H, Valore E V, Waring A J, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 2001; 276: 7806–7810
   PubMed Web of Science ®Google Scholar
• Nicolas G, Bennoun M, Devaux I, Beaumont C, Grandchamp B, Kahn A, et al. Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. Proc Natl Acad Sci USA 2001; 98: 8780–8785
   PubMed Web of Science ®Google Scholar
• Nicolas G, Bennoun M, Porteu A, Mativet S, Beaumont C, Grandchamp B, et al. Severe iron deficiency anemia in transgenic mice expressing liver hepcidin. Proc Natl Acad Sci USA 2002; 99: 4596–4601
   PubMed Web of Science ®Google Scholar
• Donovan A, Lima C A, Pinkus J L, Pinkus G S, Zon L I, Robine S, et al. The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis. Cell Metab 2005; 1: 191–200
   PubMed Web of Science ®Google Scholar
• Nemeth E, Tuttle M S, Powelson J, Vaughn M B, Donovan A, Ward D M, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004; 306: 2090–2093
   PubMed Web of Science ®Google Scholar
• Knutson M D, Oukka M, Koss L M, Aydemir F, Wessling-Resnick M. Iron release from macrophages after erythrophagocytosis is up-regulated by ferroportin 1 overexpression and down-regulated by hepcidin. Proc Natl Acad Sci USA 2005; 102: 1324–1328
   PubMed Web of Science ®Google Scholar
• Nemeth E, Ganz T. Regulation of iron metabolism by hepcidin. Annu Rev Nutr 2006; 26: 323–342
   PubMed Web of Science ®Google Scholar
• Papanikolaou G, Tzilianos M, Christakis J I, Bogdanos D, Tsimirika K, MacFarlane J, et al. Hepcidin in iron overload disorders. Blood 2005; 105: 4103–4105
   PubMed Web of Science ®Google Scholar
• Adamsky K, Weizer O, Amariglio N, Breda L, Harmelin A, Rivella S, et al. Decreased hepcidin mRNA expression in thalassemic mice. Br J Haematol 2004; 124: 123–124
   PubMed Web of Science ®Google Scholar
• Hershko C, Graham G, Bates G W, Rachmilewitz E A. Non-specific serum iron in thalassaemia: an abnormal serum iron fraction of potential toxicity. Br J Haematol 1978; 40: 255–263
   PubMed Web of Science ®Google Scholar
• Cabantchik Z I, Breuer W, Zanninelli G, Cianciulli P. LPI-labile plasma iron in iron overload. Best Pract Res Clin Haematol 2005; 18: 277–287
   PubMed Web of Science ®Google Scholar
• Breuer W, Hershko C, Cabantchik Z I. The importance of non-transferrin bound iron in disorders of iron metabolism. Transfus Sci 2000; 23: 185–192
   PubMedGoogle Scholar
• Esposito B P, Breuer W, Sirankapracha P, Pootrakul P, Hershko C, Cabantchik Z I. Labile plasma iron in iron overload: redox activity and susceptibility to chelation. Blood 2003; 102: 2670–2677
   PubMed Web of Science ®Google Scholar
• Pootrakul P, Breuer W, Sametband M, Sirankapracha P, Hershko C, Cabantchik Z I. Labile plasma iron (LPI) as an indicator of chelatable plasma redox activity in iron-overloaded beta-thalassemia/HbE patients treated with an oral chelator. Blood 2004; 104: 1504–1510
   PubMed Web of Science ®Google Scholar
• Hebbel R P. Auto-oxidation and a membrane-associated ‘Fenton reagent’: a possible explanation for development of membrane lesions in sickle erythrocytes. Clin Haematol 1985; 14: 129–140
   PubMedGoogle Scholar
• Le Lan C, Loreal O, Cohen T, Ropert M, Glickstein H, Laine F, et al. Redox active plasma iron in C282Y/C282Y hemochromatosis. Blood 2005; 105: 4527–4531
   PubMed Web of Science ®Google Scholar
• Hershko C, Peto T E. Non-transferrin plasma iron. Br J Haematol 1987; 66: 149–151
   PubMed Web of Science ®Google Scholar
• Link G, Pinson A, Hershko C. Heart cells in culture: a model of myocardial iron overload and chelation. J Lab Clin Med 1985; 106: 147–153
   PubMed Web of Science ®Google Scholar
• Cortelezzi A, Cattaneo C, Cristiani S, Duca L, Sarina B, Deliliers G L, et al. Non-transferrin-bound iron in myelodysplastic syndromes: a marker of ineffective erythropoiesis?. Hematol J 2000; 1: 153–158
   PubMedGoogle Scholar
• Olivieri N F, Brittenham G M. Iron-chelating therapy and the treatment of thalassemia. Blood 1997; 89: 739–761
   PubMed Web of Science ®Google Scholar
• Olivieri N F, Nathan D G, MacMillan J H, Wayne A S, Liu P P, McGee A, et al. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med 1994; 331: 574–578
   PubMed Web of Science ®Google Scholar
• Brittenham G M, Griffith P M, Nienhuis A W, McLaren C E, Young N S, Tucker E E, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994; 331: 567–573
   PubMed Web of Science ®Google Scholar
• Wolfe L, Olivieri N, Sallan D, Colan S, Rose V, Propper R, et al. Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major. N Engl J Med 1985; 312: 1600–1603
   PubMed Web of Science ®Google Scholar
• Iancu T C NH, Landing B H. The liver in thalassemia major: ultra-structural observations. Iron Metab Ciba Foundation Symp 1977; 51: 293–307
   Google Scholar
• Thakerngpol K, Fucharoen S, Boonyaphipat P, Srisook K, Sahaphong S, Vathanophas V, et al. Liver injury due to iron overload in thalassemia: histopathologic and ultrastructural studies. Biometals 1996; 9: 177–183
   PubMed Web of Science ®Google Scholar
• Gamberini M R, Fortini M, De Sanctis V, Gilli G, Testa M R. Diabetes mellitus and impaired glucose tolerance in thalassaemia major: incidence, prevalence, risk factors and survival in patients followed in the Ferrara Center. Pediatr Endocrinol Rev 2004; 2(Suppl 2)285–291
   PubMedGoogle Scholar
• Niederau C, Fischer R, Sonnenberg A, Stremmel W, Trampisch H J, Strohmeyer G. Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. N Engl J Med 1985; 313: 1256–1262
   PubMed Web of Science ®Google Scholar
• Wojcik J P, Speechley M R, Kertesz A E, Chakrabarti S, Adams P C. Natural history of C282Y homozygotes for hemochromatosis. Can J Gastroenterol 2002; 16: 297–302
   PubMed Web of Science ®Google Scholar
• Olivieri N F, Brittenham G M, Matsui D, Berkovitch M, Blendis L M, Cameron R G, et al. Iron-chelation therapy with oral deferipronein patients with thalassemia major. N Engl J Med 1995; 332: 918–922
   PubMed Web of Science ®Google Scholar
• Brittenham G M, Sheth S, Allen C J, Farrell D E. Non-invasive methods for quantitative assessment of transfusional iron overload in sickle cell disease. Semin Hematol 2001; 38: 37–56
   PubMed Web of Science ®Google Scholar
• Fischer R, Longo F, Nielsen P, Engelhardt R, Hider R C, Piga A. Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with beta-thalassaemia major: application of SQUID biomagnetic liver susceptometry. Br J Haematol 2003; 121: 938–948
   PubMed Web of Science ®Google Scholar
• St. Pierre T G, Clark P R, Chua-anusorn W, Fleming A J, Jeffrey G P, Olynyk J K, et al. Non-invasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood 2005; 105: 855–861
   PubMed Web of Science ®Google Scholar
• Anderson L J, Holden S, Davis B, Prescott E, Charrier C C, Bunce N H, et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 2001; 22: 2171–2179
   PubMed Web of Science ®Google Scholar
• Robins-Browne R M, Prpic J K. Effects of iron and desferrioxamine on infections with Yersinia enterocolitica. Infect Immun 1985; 47: 774–779
   PubMed Web of Science ®Google Scholar
• Ribes J A, Vanover-Sams C L, Baker D J. Zygomycetes in human disease. Clin Microbiol Rev 2000; 13: 236–301
   PubMed Web of Science ®Google Scholar
• Olivieri N F, Koren G, Hermann C, Bentur Y, Chung D, Klein J, et al. Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients. Lancet 1990; 336: 1275–1279
   PubMed Web of Science ®Google Scholar
• Cohen A R, Galanello R, Piga A, De Sanctis V, Tricta F. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood 2003; 102: 1583–1587
   PubMed Web of Science ®Google Scholar
• Daar S, Pathare A V. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload. Ann Hematol 2006; 85: 315–319
   PubMed Web of Science ®Google Scholar
• Tanner M A, Galanello R, Dessi C, Smith G C, Westwood M A, Agus A, et al. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation 2007; 115: 1876–1884
   PubMed Web of Science ®Google Scholar
• Pennell D J, Berdoukas V, Karagiorga M, Ladis V, Piga A, Aessopos A, et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood 2006; 107: 3738–3744
   PubMed Web of Science ®Google Scholar
• Borgna-Pignatti C, Cappellini M D, De Stefano P, Del Vecchio G C, Forni G L, Gamberini M R, et al. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood 2006; 107: 3733–3737
   PubMed Web of Science ®Google Scholar
• Cohen A R. New advances in iron chelation therapy. Hematol Am Soc Hematol Educ Program 2006; 42–47
   PubMedGoogle Scholar
• Cappellini M D, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 2006; 107: 3455–3462
   PubMed Web of Science ®Google Scholar
• Armand P, Kim H T, Cutler C S, Ho V T, Koreth J, Alyea E P, et al. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood 2007; 109: 4586–4588
   PubMed Web of Science ®Google Scholar
• Takatoku T U, Okamoto S, Kanakura Y, Sawada K, Tomonaga M, Nakao S, et al. Retrospective survey of Japanese patients with transfusion-dependent myelodysplastic syndromes and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality. Blood 2006; 108
   Google Scholar
• Jensen P D, Heickendorff L, Pedersen B, Bendix-Hansen K, Jensen F T, Christensen T, et al. The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload. Br J Haematol 1996; 94: 288–299
   PubMed Web of Science ®Google Scholar
• Leitch H, Goodman T A, Wong K, Vickars L, Galbraith P, Leger C, et al. Improved survival in patients with myelodysplastic syndrome (MDS) receiving iron chelation therapy. Blood 2006; 108
   Google Scholar
• Greenberg P L, Baer M R, Bennett J M, Bloomfield C D, De Castro C M, Deeg H J, et al. Myelodysplastic syndromes clinical practice guidelines in oncology. J Natl Compr Canc Netw 2006; 4: 58–77
   PubMedGoogle Scholar
• Thuret CB-S, Bachir D, Hacini M, Pegourie-Bandelier B, Gardembas-Pain M, (Intr. by Renaud Capdeville). Patient characteristics, quality-of-life and compliance with deferoxamine in patients with transfusional iron overload: results of ISOSFER Study. Blood 2006; 1085513.
   Google Scholar
• Brun-Strang C BD, De Montalembert M, Thuret I. Socio-economic impact of infused iron chelation therapy in France: ISOSFER Study results. Blood 2006; 1083354.
   Google Scholar
• Delea T E, Sofrygin O, Thomas S K, Baladi J F, Phatak P D, Coates T D. Cost effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalassaemia patients: US healthcare system perspective. Pharmacoeconomics 2007; 25: 329–342
   PubMed Web of Science ®Google Scholar
• Nisbet-Brown E, Olivieri N F, Giardina P J, Grady R W, Neufeld E J, Sechaud R, et al. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2003; 361: 1597–1602
   PubMed Web of Science ®Google Scholar
• Piga A, Galanello R, Forni G L, Cappellini M D, Origa R, Zappu A, et al. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica 2006; 91: 873–880
   PubMed Web of Science ®Google Scholar